Abstract: A detecting device includes a turntable, a rotating device, a sound generating device, and a processing device. The turntable has a first surface and a second surface opposite to the first surface, and the first surface is used to dispose a device to be tested. The rotating device is connected to the second surface of the turntable for driving to rotate the turntable. The sound generating device is used to emit a test audio toward the device to be tested. The processing device is connected to the rotating device and the sound generating device. Among them, the processing device controls a rotational speed of the rotating device to rotate the device to be tested, and controls the sound generating device to emit the test audio to the device to be tested such that the device to be tested may receive the test audio at different angles.

Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

Abstract: A method, system and computer program product for processing messages sent to a recipient. The communication channel used to send the message is identified, where such a communication channel is not currently being used by the recipient. After identifying the communication channel(s) currently being used by the recipient, the contact information of users who have previously communicated with the recipient using the communication channel(s) currently being used by the recipient are analyzed. The message is then marked with the identity of the sender as well as the communication channel used by the sender after matching the contact information of the sender with the contact information of a user who had previously communicated with the recipient using the communication channel(s) currently being used by the recipient. The marked message is then sent to the recipient using a communication channel currently being used by the recipient.

Abstract: A high-rate lithium cobaltate cathode material, which contains a multi-channel network formed by fast ionic conductor Li?M??O?, mainly consists of lithium cobaltate. The lithium cobaltate is melted together with the fast ionic conductor Li?M??O? in the form of primary particles to form secondary particles. Besides, the lithium cobaltate is embedded in the multi-channel network formed by fast ionic conductor Li?M??O?. The element M? in Li?M??O? is one or more of Ti, Zr, Y, V, Nb, Mo, Sn, In, La, W and 1???4, 1???5, 2???12. The lithium cobaltate cathode material is mainly obtained by uniformly mixing cobaltous oxide impregnated with a hydroxide of M? and lithium source, then by the sintering reaction in an air atmosphere furnace at a high temperature. The product of the present invention can greatly promote the lithium ion conductivity of the lithium cobaltate cathode material during the charging and discharging process of the lithium-ion battery, and improve the rate performance of the material.

Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

Abstract: Underfill materials for fabricating electronic devices are described. One embodiment includes an underfill composition including an epoxy mixture, an amine hardener component, and a filler. The epoxy mixture may include a first epoxy comprising a bisphenol epoxy, a second epoxy comprising a multifunctional epoxy, and a third epoxy comprising an aliphatic epoxy, the aliphatic epoxy comprising a silicone epoxy. The first, second, and third epoxies each have a different chemical structure. Other embodiments are described and claimed.

Abstract: Underfill materials for fabricating electronic devices are described. One embodiment includes an underfill composition including an epoxy mixture, an amine hardener component, and a filler. The epoxy mixture may include a first epoxy comprising a bisphenol epoxy, a second epoxy comprising a multifunctional epoxy, and a third epoxy comprising an aliphatic epoxy, the aliphatic epoxy comprising a silicone epoxy. The first, second, and third epoxies each have a different chemical structure. Other embodiments are described and claimed.

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

Abstract: The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).

Abstract: Underfill materials for fabricating electronic devices are described. One embodiment includes an underfill composition including an epoxy mixture, an amine hardener component, and a filler. The epoxy mixture may include a first epoxy comprising a bisphenol epoxy, a second epoxy comprising a multifunctional epoxy, and a third epoxy comprising an aliphatic epoxy, the aliphatic epoxy comprising a silicone epoxy. The first, second, and third epoxies each have a different chemical structure. Other embodiments are described and claimed.

Abstract: A cell phone protector case including a front cavity to retain a cell phone. It further includes a rear recessed cavity having a recessed rear wall surrounded by a circumferential rim including a first sidewall, a second sidewall, a first width-wise wall and a second width-wise wall, the recessed rear wall having a width-wise dimension and a lengthwise dimension and extends for a depth “below the tops of the respective lengthwise sidewalls and the width-wise walls. A key unique feature is the inclusion of a sheet of drawing, sketching or artwork paper having a front surface and a rear surface dimensioned to fit within the rear recessed cavity and retained by the rear sidewalls and rear width-wise walls.

Abstract: The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).

Abstract: Nanocellulose foams containing at least one active ingredient and methods of preparing such nanocellulose foams containing one or more active ingredients are provided herein. In some embodiments, a method for preparing nanocellulose foam containing active ingredients may include forming a liquid mixture of nanocellulose, wherein the nanocellulose is at least one of dispersed, suspended or gelled in the liquid mixture; drying the liquid mixture of nanocellulose to form a nanocellulose foam; and mixing at least one active ingredient into at least one of the liquid mixture of nanocellulose or the nanocellulose foam. In some embodiments, a nanocellulose structure may include a nanocellulose foam comprising at least one of a carboxylate group, a hydroxyl group, or a sulfate group bonded to an active ingredient. In some embodiments, the nanocellulose structures are enhanced or crosslinked with metal cations.

Abstract: A method, system and media server for creating a multicast channel, wherein, the method for creating a multicast channel includes: a media server receiving a command for creating a multicast channel from a client, the command carrying a channel number and a multicast address of the multicast channel to be created and an interface address of the media server; the media server binding, according to the command, the multicast channel identified by the channel number to the interface identified by the interface address of the media server, and obtaining port information of the interface; the media server creating, according to the port information and the multicast address, the multicast channel from a port identified by the port information to a multicast group identified by the multicast address.